Compare STRL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRL | NBIX |
|---|---|---|
| Founded | 1955 | 1992 |
| Country | United States | United States |
| Employees | 1740 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 15.5B |
| IPO Year | 1996 | 1996 |
| Metric | STRL | NBIX |
|---|---|---|
| Price | $526.34 | $145.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 28 |
| Target Price | ★ $845.43 | $207.81 |
| AVG Volume (30 Days) | 459.9K | ★ 1.2M |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.42 | ★ 41.95 |
| EPS | ★ 8.09 | 3.30 |
| Revenue | ★ $957,958,000.00 | $161,626,000.00 |
| Revenue This Year | $64.87 | $36.49 |
| Revenue Next Year | $19.86 | $16.51 |
| P/E Ratio | $62.44 | ★ $42.64 |
| Revenue Growth | 38.81 | ★ 977.51 |
| 52 Week Low | $281.58 | $122.14 |
| 52 Week High | $1,005.68 | $186.12 |
| Indicator | STRL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 45.12 |
| Support Level | $492.71 | $125.85 |
| Resistance Level | $531.00 | $161.41 |
| Average True Range (ATR) | 22.10 | 3.88 |
| MACD | 4.97 | 0.14 |
| Stochastic Oscillator | 85.00 | 43.89 |
Sterling Infrastructure Inc operates through subsidiaries within three segments: E-Infrastructure, Transportation, and Building Solutions in the United States, mainly across the Southern, Northeastern, Mid-Atlantic, and Rocky Mountain regions and the Pacific Islands. E-Infrastructure Solutions generates maximum revenue and provides site development and mission-critical electrical services for data centers, manufacturing, distribution centers, warehousing, and power generation. Transportation Solutions includes infrastructure and rehabilitation projects for highways, airports, ports, rail, and storm drainage systems. Building Solutions includes residential and commercial concrete foundations, parking structures, plumbing services, and surveys for new single-family residential builds.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.